New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 22, 2014
09:07 EDTSRPTSarepta must enhance dataset for acceptable NDA filing, says Janney Capital
Janney Capital noted that the FDA said Sarepta's current dataset is not strong enough alone to file an adequate NDA for eteplirsen for Duchenne Muscular Dystrophy. The FDA suggested a fourth muscle biopsy in Study 202 patients, but Janney believes the company may be challenged to convince patients to undergo such surgeries. The firm maintains its Sell rating and $10 fair value estimate on shares of Sarepta.
News For SRPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 6, 2015
10:24 EDTSRPTOptions with increasing implied volatility
Options with increasing implied volatility: UVXY MBI AMBC VIX FIT SRPT VXX GREK SVXY GNW
July 2, 2015
10:48 EDTSRPTOptions with increasing implied volatility
Subscribe for More Information
June 30, 2015
10:26 EDTSRPTOptions with increasing implied volatility
Subscribe for More Information
June 29, 2015
12:53 EDTSRPTSarepta NDA submission for eteplirsen done ahead of schedule, says Piper Jaffray
Piper Jaffray noted that Sarepta (SRPT) completed its rolling NDA submission for eteplirsen ahead of schedule and the firm believes that concurrent advisory committee meetings for its DMD drug and BioMarin's (BMRN) drisapersen could take place this fall. The firm has a Neutral rating and $20 price target on Sarepta and Overweight rating and $147 target on BioMarin.
07:05 EDTSRPTSarepta completes NDA submission to FDA for eteplirsen
Subscribe for More Information
07:03 EDTSRPTSarepta secures $40M in debt financing
Sarepta Therapeutics announced that it entered into a credit and security agreement with Midcap Financial, a middle market-focused, specialty finance firm, that establishes a senior secured term loan facility that allows Sarepta to borrow up to $40M at an annual rate of 7.75%, with a maturity of June 2018, subject to certain conditions and other applicable fees. Sarepta has drawn down $20M under the facility and has the right to repay all borrowed funds and terminate the facility at any time.
June 26, 2015
11:00 EDTSRPTOptions with increasing implied volatility
Options with increasing implied volatility: SRPT AGO CRC WMB AMZN CMG TRIP ZTS AET MBI
June 25, 2015
12:59 EDTSRPTOptions with increasing implied volatility
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use